Clinical trial
A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
NCT04945733 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 30, 2021
- Completion date
- July 3, 2023
- Enrollment
- 62 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.